- Home
- RPRX vs LI Comparison
RPRX vs LI Comparison
Compare RPRX & LI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | LI |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 17.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RPRX | LI |
|---|---|---|
| Price | $41.24 | $16.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $45.75 | $20.91 |
| AVG Volume (30 Days) | 3.4M | ★ 4.2M |
| Earning Date | 02-10-2026 | 11-26-2025 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.75 | 0.62 |
| Revenue | $2,349,844,000.00 | ★ $17,952,966,790.00 |
| Revenue This Year | $37.66 | N/A |
| Revenue Next Year | $2.34 | $26.33 |
| P/E Ratio | ★ $23.21 | $27.36 |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $25.40 | $16.11 |
| 52 Week High | $41.24 | $33.12 |
Technical Indicators
Market Signals| Indicator | RPRX | LI |
|---|---|---|
| Relative Strength Index (RSI) | 70.38 | 42.26 |
| Support Level | $38.29 | $16.82 |
| Resistance Level | $39.46 | $17.74 |
| Average True Range (ATR) | 0.64 | 0.42 |
| MACD | 0.21 | 0.15 |
| Stochastic Oscillator | 97.91 | 50.61 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.